Neurocrine achieves a first with tardive dyskinesia drug IngrezzaThe FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The Share XNeurocrine achieves a first with tardive dyskinesia drug Ingrezzahttps://pharmaphorum.com/news/ingrezza-approved/
